Oxeia Biopharmaceuticals develops novel therapeutics for patients with concussions.Because rest is not enough What’s New… Oxeia Biopharma In the News Neurotrauma Reports: Injection of Ghrelin (OXE-103) Improves Subacute Concussion Symptom Burden and Quality of Life Neuro Rehab Times: Exploring the gap in traumatic brain injury and concussion treatment GEN: Light Within the Black Hole of Concussion Therapeutics NB Science Cafe: Dr. Michael Wyand Drug Discovery World Podcast: The unmet critical need for concussion drug therapies These stories and more… Read more... Oxeia Biopharmaceuticals is a team of passionate scientists, biotech leaders, and athletes dedicated to bringing a safe and effective concussion therapy to market.REST IS NOT ENOUGH. More About What We Do